| scholarly article | Q13442814 |
| P2093 | author name string | Yuri Sanchez Gonzalez | |
| Bruce S Pyenson | |||
| Gabriela Dieguez | |||
| Maushumi Mavinkurve | |||
| Christine Ferro | |||
| P2860 | cites work | Extrahepatic manifestations of chronic hepatitis C virus infection | Q26767084 |
| Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence | Q28072257 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 | Q29620136 | ||
| Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. | Q34294185 | ||
| The HHS-HCC risk adjustment model for individual and small group markets under the Affordable Care Act | Q34426576 | ||
| Sexually transmitted diseases treatment guidelines, 2015. | Q34479272 | ||
| Toward a more accurate estimate of the prevalence of hepatitis C in the United States | Q34484872 | ||
| Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force | Q34489162 | ||
| Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 | Q36035889 | ||
| Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008 | Q36100389 | ||
| Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea. | Q36242517 | ||
| Chronic hepatitis C virus (HCV) disease burden and cost in the United States | Q37148328 | ||
| Hepatitis C comorbidities affecting the course and response to therapy | Q37402438 | ||
| All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective | Q37922772 | ||
| The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society? | Q38996459 | ||
| Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013. | Q40769735 | ||
| The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus | Q41207230 | ||
| Cost-effectiveness of novel regimens for the treatment of hepatitis C virus | Q41211125 | ||
| Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs | Q41632410 | ||
| The cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings | Q41919051 | ||
| The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. | Q41923187 | ||
| Patient Protection and Affordable Care Act; program integrity: exchange, premium stabilization programs, and market standards; amendments to the HHS notice of benefit and payment parameters for 2014. Final rule | Q43851845 | ||
| Potential epidemiologic, economic, and budgetary impacts of current rates of hepatitis C treatment in medicare and non-medicare populations. | Q55163317 | ||
| New Expensive Treatments for Hepatitis C Infection | Q57255675 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 30-37 | |
| P577 | publication date | 2018-02-01 | |
| P1433 | published in | American health & drug benefits | Q26842282 |
| P1476 | title | Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines. | |
| P478 | volume | 11 |
Search more.